Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by Golden State Equity Partners

Golden State Equity Partners grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 19.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,454 shares of the medical equipment provider’s stock after buying an additional 239 shares during the quarter. Golden State Equity Partners’ holdings in Intuitive Surgical were worth $491,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Cornerstone Capital Inc. boosted its stake in Intuitive Surgical by 0.3% during the fourth quarter. Cornerstone Capital Inc. now owns 13,261 shares of the medical equipment provider’s stock valued at $4,474,000 after buying an additional 45 shares in the last quarter. Kovack Advisors Inc. boosted its stake in Intuitive Surgical by 29.2% during the fourth quarter. Kovack Advisors Inc. now owns 1,350 shares of the medical equipment provider’s stock valued at $455,000 after buying an additional 305 shares in the last quarter. Bahl & Gaynor Inc. boosted its stake in Intuitive Surgical by 5.1% during the fourth quarter. Bahl & Gaynor Inc. now owns 11,656 shares of the medical equipment provider’s stock valued at $3,932,000 after buying an additional 570 shares in the last quarter. Motley Fool Asset Management LLC boosted its stake in Intuitive Surgical by 6.7% during the fourth quarter. Motley Fool Asset Management LLC now owns 10,457 shares of the medical equipment provider’s stock valued at $3,528,000 after buying an additional 657 shares in the last quarter. Finally, Wisconsin Capital Management LLC boosted its stake in Intuitive Surgical by 6.1% during the fourth quarter. Wisconsin Capital Management LLC now owns 7,455 shares of the medical equipment provider’s stock valued at $2,515,000 after buying an additional 428 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

ISRG opened at $375.33 on Friday. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The business has a 50-day moving average of $386.19 and a 200-day moving average of $346.29. The company has a market capitalization of $133.13 billion, a PE ratio of 67.75, a price-to-earnings-growth ratio of 4.85 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same period last year, the business earned $1.00 EPS. The business’s quarterly revenue was up 11.5% on a year-over-year basis. On average, equities research analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, EVP Robert Desantis sold 20,296 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the completion of the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Robert Desantis sold 20,296 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $393.80, for a total value of $7,992,564.80. Following the transaction, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Marshall Mohr sold 108,790 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the transaction, the vice president now directly owns 26,877 shares in the company, valued at $10,349,795.16. The disclosure for this sale can be found here. Insiders sold 249,418 shares of company stock valued at $96,300,959 in the last three months. Corporate insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Barclays increased their price target on Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research report on Thursday, January 25th. Mizuho increased their price target on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Raymond James increased their price target on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. BTIG Research increased their price target on Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Finally, Jefferies Financial Group increased their price target on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.